Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension

BACKGROUND: Bimatoprost 0.01% was developed for improved tolerability over bimatoprost 0.03%, while maintaining efficacy in lowering intraocular pressure (IOP). This multicenter, prospective, open-label, observational study was designed to investigate the efficacy and tolerability of bimatoprost 0.0...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfennigsdorf, Stefan, Ramez, Osman, von Kistowski, Gerrit, Mäder, Birgit, Eschstruth, Peter, Froböse, Michael, Thelen, Ulrich, Spraul, Christoph, Schnober, Dietmar, Cooper, Hazel, Laube, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363312/
https://www.ncbi.nlm.nih.gov/pubmed/22654501
http://dx.doi.org/10.2147/OPTH.S31330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363312/
https://www.ncbi.nlm.nih.gov/pubmed/22654501
http://dx.doi.org/10.2147/OPTH.S31330

Ejemplares similares